A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years
NCT06735248
This study is recruiting at 6 US sites in 4 states, according to its ClinicalTrials.gov record last updated .
Summary
The primary objective of this trial is to evaluate the safety and reactogenicity of mRNA-1195 in participants with multiple sclerosis.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Multiple Sclerosis
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 to 55 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- ModernaTX, Inc.
- Last updated on ClinicalTrials.gov
- June 15, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Michigan · 1
- Quest Research Institute · Farmington Hills, MI
Missouri · 1
- Washington University School of Medicine Neurology Clinical Unit · St Louis, MO
Oklahoma · 1
- Oklahoma Medical Research Foundation (OMRF) MS Center of Excellence · Oklahoma City, OK
Texas · 3
- University of Texas Southwestern Medical Center · Dallas, TX
- ANESC Research · El Paso, TX
- Saturn Research Solutions · Plano, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.